Table 3.
Participant characteristics by clinical diagnosis and elevated brain Aβ PET
| CU A- (N = 100) | CU A+ (N = 72) | MCI A- (N = 29) | MCI A+ (N = 28) | AD A+ (N = 38) | |||
|---|---|---|---|---|---|---|---|
| Mean (SD)/N(%) | Mean (SD)/N(%) | Mean (SD)/N(%) | Mean (SD)/N(%) | Mean (SD)/N(%) | F value | P value | |
| Plasma phospho-tau 181 | 6.0 (7.6) | 6.9 (4.1) | 6.7 (10.8) | 11.3 (16.5) | 12.0 (3.8) | 5.11 | < .001 |
| Plasma total tau | 5.8 (2.0) | 6.0 (1.7) | 5.4 (1.3) | 6.4 (3.7) | 7.2 (2.9) | 3.45 | .009 |
| Age | 70.4 (9.8) | 74.0 (8.8) | 66.7 (9.3) | 76.3 (10.0) | 67.2 (9.2) | 7.14 | < .001 |
| Male | 72 (72.0%) | 47 (65.3%) | 27 (93.1%) | 18 (64.3%) | 22 (57.9%) | .023 | |
| Education | 15.4 (2.4) | 15.0 (2.7) | 15.0 (3.6) | 14.9 (2.9) | 15.1 (2.8) | 0.34 | .853 |
| APOE ε4 | 16 (16.0%) | 34 (47.2%) | 5 (17.2%) | 15 (53.6%) | 28 (73.7%) | < .001 | |
| Aβ PET SUVR | 1.3 (0.1) | 1.8 (0.4) | 1.3 (0.1) | 2.2 (0.5) | 2.5 (0.4) | 146.82 | < .001 |
| Aβ PET>1.42 SUVR | 0 (0%) | 72 (100%) | 0 (0%) | 28 (100%) | 38 (100%) | < .001 | |
| Tau PET entorhinal cortex | 1.1 (0.1) | 1.1 (0.1) | 1.1 (0.1) | 1.3 (0.3) | 1.8 (0.3) | 131.50 | < .001 |
| Cortical thickness | 2.7 (0.1)) | 2.7 (0.2) | 2.7 (0.2) | 2.6 (0.2) | 2.3 (0.2) | 40.23 | < .001 |
| Cortical thickness<2.67mm | 34 (34.0%) | 34 (47.2%) | 13 (44.9%) | 22 (78.6%) | 35 (94.6%) | < .001 |
Abbreviations: AD, Alzheimer’s disease dementia; Aβ, amyloid-beta; APOE, apolipoprotein E; CU, cognitively unimpaired; IQR, interquartile range; MCI, mild cognitive impairment; PET, positron emission tomography; SUVR, standardized uptake value ratio.
*
Analyses of group differences included chi-square tests for dichotomous variables and ANOVA for continuous variables.